雄激素剥夺疗法治疗前列腺癌——2010 年适应证的回顾。
Androgen deprivation therapy for prostate cancer-review of indications in 2010.
机构信息
Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON.
出版信息
Curr Oncol. 2010 Sep;17 Suppl 2(Suppl 2):S38-44. doi: 10.3747/co.v17i0.698.
Abstract
The discovery of androgen deprivation therapy (ADT) has been one of the most important advances in the treatment of prostate cancer. Here, the indications for the use of ADT are reviewed, together with the data supporting each indication. The settings for ADT use include cytoreduction; combined ADT and radiotherapy; pathologic node-positive disease; and recurrent, metastatic, or progressive prostate cancer.
摘要
雄激素剥夺疗法 (ADT) 的发现是前列腺癌治疗中最重要的进展之一。本文回顾了 ADT 的适应证，并介绍了支持每种适应证的数据。ADT 的应用场景包括细胞减灭术；联合 ADT 和放疗；病理淋巴结阳性疾病；以及复发性、转移性或进展性前列腺癌。
相似文献
1
Androgen deprivation therapy for prostate cancer-review of indications in 2010.
Curr Oncol. 2010 Sep;17 Suppl 2(Suppl 2):S38-44. doi: 10.3747/co.v17i0.698.
2
Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use?
BJU Int. 2011 Nov;108(10):1588-96. doi: 10.1111/j.1464-410X.2011.10127.x. Epub 2011 Mar 31.
3
Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1493-9. doi: 10.1016/j.ijrobp.2011.10.047. Epub 2012 Mar 6.
4
[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Actas Urol Esp. 2011 Nov-Dec;35(10):565-79. doi: 10.1016/j.acuro.2011.03.011. Epub 2011 Jul 14.
5
Adherence to guidelines for androgen deprivation therapy after radical prostatectomy: Swedish population-based study.
Scand J Urol. 2020 Jun;54(3):208-214. doi: 10.1080/21681805.2020.1750475. Epub 2020 Apr 27.
6
Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
Eur Urol. 2018 Apr;73(4):512-518. doi: 10.1016/j.eururo.2017.11.020. Epub 2017 Dec 8.
7
Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer.
Expert Opin Pharmacother. 2017 Jan;18(1):105-113. doi: 10.1080/14656566.2016.1258058. Epub 2016 Nov 28.
8
Androgen deprivation therapy in men with node-positive prostate cancer treated with postoperative radiotherapy.
Urol Oncol. 2020 Apr;38(4):204-209. doi: 10.1016/j.urolonc.2019.09.018. Epub 2019 Oct 23.
9
Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks.
Eur Urol. 2009 Jan;55(1):62-75. doi: 10.1016/j.eururo.2008.10.008. Epub 2008 Oct 14.
10
Androgen deprivation therapy during and after post-prostatectomy radiotherapy in patients with prostate cancer: a case control study.
BMC Cancer. 2018 Mar 9;18(1):271. doi: 10.1186/s12885-018-4189-9.
引用本文的文献
1
Network meta-analysis of combination strategies in metastatic hormone-sensitive prostate cancer.
Asian J Androl. 2024 Jul 1;26(4):402-408. doi: 10.4103/aja20242. Epub 2024 Apr 12.
2
Metabolic Interplay in the Tumor Microenvironment: Implications for Immune Function and Anticancer Response.
Curr Issues Mol Biol. 2023 Dec 5;45(12):9753-9767. doi: 10.3390/cimb45120609.
3
Antagonizing RARγ Drives Necroptosis of Cancer Stem Cells.
Int J Mol Sci. 2022 Apr 27;23(9):4814. doi: 10.3390/ijms23094814.
4
Clinical Outcomes from Dose-Reduced Radiotherapy to the Prostate in Elderly Patients with Localized Prostate Cancer.
Curr Oncol. 2021 Sep 26;28(5):3729-3737. doi: 10.3390/curroncol28050318.
5
The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer.
Cancer Manag Res. 2019 Dec 2;11:10125-10133. doi: 10.2147/CMAR.S213419. eCollection 2019.
6
Rapid bench to bed in management of metastatic prostate cancer.
Indian J Urol. 2016 Oct-Dec;32(4):255-256. doi: 10.4103/0970-1591.189720.
7
Formulation and evaluation of PLGA nanoparticles loaded capecitabine for prostate cancer.
Int J Clin Exp Med. 2015 Oct 15;8(10):19670-81. eCollection 2015.
8
Matrine inhibits the proliferation, invasion and migration of castration-resistant prostate cancer cells through regulation of the NF-κB signaling pathway.
Oncol Rep. 2016 Jan;35(1):375-81. doi: 10.3892/or.2015.4341. Epub 2015 Oct 21.
9
To die or to survive, a fatal question for the destiny of prostate cancer cells after androgen deprivation therapy.
Cancers (Basel). 2011 Mar 24;3(2):1498-512. doi: 10.3390/cancers3021498.
10
Be it resolved that in the modern era, the best method for dose escalation is brachytherapy: The con position.
Can Urol Assoc J. 2012 Jun;6(3):199-201. doi: 10.5489/cuaj.12122.
本文引用的文献
1
Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09.
J Clin Oncol. 2010 Mar 1;28(7):1106-11. doi: 10.1200/JCO.2009.25.8475. Epub 2010 Feb 1.
2
Hormone use after radiotherapy failure: a survey of Canadian uro-oncology specialists.
Can Urol Assoc J. 2009 Dec;3(6):460-4. doi: 10.5489/cuaj.1175.
3
Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.
J Clin Oncol. 2010 Jan 1;28(1):126-31. doi: 10.1200/JCO.2009.24.2180. Epub 2009 Nov 16.
4
Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival.
Cancer. 2009 Aug 1;115(15):3437-45. doi: 10.1002/cncr.24395.
5
Duration of androgen suppression in the treatment of prostate cancer.
N Engl J Med. 2009 Jun 11;360(24):2516-27. doi: 10.1056/NEJMoa0810095.
6
Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse.
Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):983-9. doi: 10.1016/j.ijrobp.2008.12.049. Epub 2009 May 4.
7
Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins.
Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):407-12. doi: 10.1016/j.ijrobp.2008.11.007. Epub 2009 Feb 11.
8
Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial.
J Urol. 2009 Mar;181(3):956-62. doi: 10.1016/j.juro.2008.11.032. Epub 2009 Jan 23.
9
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Lancet. 2009 Jan 24;373(9660):301-8. doi: 10.1016/S0140-6736(08)61815-2. Epub 2008 Dec 16.
10
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
BJU Int. 2008 Dec;102(11):1531-8. doi: 10.1111/j.1464-410X.2008.08183.x.
Zotero 插件